4521 — Kaken Pharmaceutical Co Share Price
- ¥147bn
- ¥84bn
- ¥72bn
- 74
- 53
- 86
- 86
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 18.82 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -28.98% | ||
Dividend Yield (f) | 3.87% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.03 | ||
Price to Tang. Book | 1.09 | ||
Price to Free Cashflow | 358.28 | ||
Price to Sales | 2.04 | ||
EV to EBITDA | 7.67 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.41% | ||
Return on Equity | 5.2% | ||
Operating Margin | 11.37% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | ¥m | 89,232 | 74,979 | 76,034 | 72,984 | 72,044 | 83,100 | 65,900 | -5.21% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +12.24 | -31.92 | -6.87 | -41.51 | +18.54 | +60.5 | -79.76 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
Directors
- Tetsuo Ohnuma CHM (69)
- Hiroyuki Horiuchi PRE (59)
- Hirofumi Fujii EXO
- Naoyuki Ishida EXO
- Norihide Oizumi EXO
- Masanao Shimano EXO
- Suzudo Masaru OTH (58)
- Makoto Matsuura DRC (51)
- Minoru Ota DRC (62)
- Yasutomo Inoue IND (61)
- Keiko Kamibeppu IND (66)
- Shoichiro Takagi IND (60)
- Yoshio Tanabe NID (66)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- March 1st, 1948
- Public Since
- October 2nd, 1961
- No. of Shareholders
- 12,875
- No. of Employees
- 1,135
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 37,869,677
- Address
- 20F, Bunkyo Green Court Center Office, BUNKYO-KU, 113-8650
- Web
- https://www.kaken.co.jp/
- Phone
- +81 359775001
- Auditors
- ARK & Co,
Upcoming Events for 4521
Q3 2025 Kaken Pharmaceutical Co Ltd Earnings Release
Dividend For 4521.T - 75.0000 JPY
Similar to 4521
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 21:31 UTC, shares in Kaken Pharmaceutical Co are trading at ¥3,879. This share price information is delayed by 15 minutes.
Shares in Kaken Pharmaceutical Co last closed at ¥3,879 and the price had moved by +11.69% over the past 365 days. In terms of relative price strength the Kaken Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -9.85% over the past year.
The overall consensus recommendation for Kaken Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Kaken Pharmaceutical Co dividend yield is 3.87% based on the trailing twelve month period.
Last year, Kaken Pharmaceutical Co paid a total dividend of ¥150, and it currently has a trailing dividend yield of 3.87%.Looking ahead, shares in Kaken Pharmaceutical Co are due to go ex-dividend on 2025-03-28 and the next dividend pay date is 2024-12-01.
Kaken Pharmaceutical Co are due to go ex-dividend on 2025-03-28 and the next dividend pay date is 2024-12-01. The historic dividend yield on Kaken Pharmaceutical Co shares is currently 3.87%.
To buy shares in Kaken Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥3,879, shares in Kaken Pharmaceutical Co had a market capitalisation of ¥147bn.
Here are the trading details for Kaken Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4521
Based on an overall assessment of its quality, value and momentum Kaken Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kaken Pharmaceutical Co is ¥3,600. That is 7.19% below the last closing price of ¥3,879.
Analysts covering Kaken Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥354 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kaken Pharmaceutical Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +13.97%.
As of the last closing price of ¥3,879, shares in Kaken Pharmaceutical Co were trading +5.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kaken Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 18.82. The shares last closed at ¥3,879.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kaken Pharmaceutical Co's management team is headed by:
- Tetsuo Ohnuma - CHM
- Hiroyuki Horiuchi - PRE
- Hirofumi Fujii - EXO
- Naoyuki Ishida - EXO
- Norihide Oizumi - EXO
- Masanao Shimano - EXO
- Suzudo Masaru - OTH
- Makoto Matsuura - DRC
- Minoru Ota - DRC
- Yasutomo Inoue - IND
- Keiko Kamibeppu - IND
- Shoichiro Takagi - IND
- Yoshio Tanabe - NID